UPDATE: Niagen Bioscience Sees FY26 Net sales Increasing between 10% - 15% YoY Excluding 2025 Revenue Attributable To The Analytical Reference Standards And Services Segment, Driven Primarily By E-Commerce Business And New Strategic Partnerships

2026 Outlook

• Net sales: Increasing between 10-15% year-over-year excluding 2025 revenue attributable to the Analytical Reference Standards and Services segment, driven primarily by e-commerce business and new strategic partnerships.
• Gross margin: Slight improvement year-over-year, driven by improvements in inventory cost and product mix.
• Sales & marketing: Increase in absolute dollars, but stable as a percentage of sales, driven by optimized investments to drive customer acquisition and support the launch of new verticals.
• Research & development: Increase in absolute dollars, driven by investment into pharmaceutical development and continued external research initiatives.
• General & administrative: $4.0 million to $5.0 million increase driven by infrastructure investments and legal expenses to support the growth of existing business and new market launches, as well as increased share-based compensation expense with the absence of credit loss recovery.